| Literature DB >> 30282990 |
Lindsay Candelaria1, Liliya V Frolova2, Brian M Kowalski1, Kateryna Artyushkova3, Alexey Serov4,5, Nikolai G Kalugin6.
Abstract
Carbon-based stationary phases for chromatographic separation have been commercially available since the 1980s. Porous graphitic carbon liquid chromatography columns are known to be highly resistant to aggressive mobile phases and extreme pH values of solvents and eluents, an important advantage compared to conventional silica-based alternatives. In our work, we demonstrate a new variant of carbon-based stationary phases for liquid chromatography, specifically developed for chiral separation. Mesoporous three-dimensional graphene nanosheets (3D GNS), functionalized with tetracyanoethylene oxide (TCNEO) and (S)-(+)-2-pyrrolidinemethanol, demonstrate pharmaceutical-grade chiral separation of model ibuprofen and thalidomide racemic mixtures when used as Chiral Stationary Phases (CSPs), with performance parameters comparable to currently commercially available CSPs. Simple covalent attachment of functionalization groups to the surface of mesoporous three-dimensional graphene nanosheets makes these carbon-based CSPs chemically stable and up to an order of magnitude less expensive than standard silica-based analogues.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30282990 PMCID: PMC6170404 DOI: 10.1038/s41598-018-33075-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1(a) The principle of HPLC chiral separation: a flow of dissolved chiral drug (racemic mixture containing both enantiomers) passes a chromatographic column filled with chiral stationary phase material (a 3D GNS-based material in our case). Due to a difference of retention time for enantiomers of opposite symmetry, one enantiomer passes the column faster than the other, so the enantiomers are separated. (b) Chromatographic separation of a chiral drug (in this case, ibuprofen in solution) with MOD3 or MOD1 3D GNS-containing stationary phase material. The colors of backgrounds indicate the mobile phase (light olive) and the stationary phase parts (cream color) of the separation process. In our experiments, positive optical rotation angle-enantiomers of ibuprofen and thalidomide passed through 3D GNS-containing separation columns faster than the corresponding negative rotation angle-enantiomers. The bottom part of the figure illustrates both chemical structure and morphology (SEM image) of mesoporous modified 3D GNS materials.
Figure 2(a) HPLC curves for experiments show separation results of racemic ibuprofen solution with (S)-(+)-2-pyrrolidinemethanol -modified 3D GNS stationary phase (50:50 vol. % mixture of MOD3 3D GNS and graphite powder). Red curve: 2.5 mg/ml solution of racemic ibuprofen in hexane; green curve: 0.8 mg/ml solution of racemic ibuprofen in hexane. (b) HPLC curves for experiments with TCNEO-modified 3D GNS stationary phase (MOD1 3D GNS mixed with graphite powder). Red curve: 0.8 mg/ml solution of racemic ibuprofen in hexane; green curve: 0.2 mg/ml solution of racemic ibuprofen in hexane.
Figure 3(a) HPLC separation curve of 0.8 mg/ml solution of racemic thalidomide in hexane with ethyl acetate, obtained with (S)-(+)-2-pyrrolidinemethanol-modified 3D GNS stationary phase (MOD3 3D GNS mixed with graphite powder). The inset shows the corresponding polarimetry result (negative angle of polarization rotation) from a flush chromatography test. (b) HPLC separation result (baseline separation) for 0.05 mg/ml solution of racemic thalidomide achieved in an experiment with TCNEO-modified 3D GNS stationary phase (MOD1 3D GNS mixed with graphite powder).
Ibuprofen separation results.
| Column type | Chiracel OJ-H (silica-based/cellulose) (ref.[ | MOD1 | MOD3 |
|---|---|---|---|
| Selectivity α | 0.9 | 4 | 12.5 |
| Retention factor | not reported directly in (ref.[ | 1 for S-(+)-ibuprofen | 1 for S-(+)-ibuprofen |
| Resolution | baseline separation (see ref.[ | baseline separation for 0.2 mg/ml | baseline separation for 0.8 mg/ml |
Thalidomide separation results.
| Column | Chiracel OJ (silica-based/cellulose)(ref.[ | MOD1 | MOD3 |
|---|---|---|---|
| Selectivity α | 1.54 | 17.5 | 3.3 |
| Retention factor | 9.67 for R-(+)-thalidomide (see ref.[ | 0.5 for R-(+)-thalidomide | 0.4 for R-(+)-thalidomide |
| Resolution | 15.5 (see ref.[ | baseline separation for 0.05 mg/ml | 0.55 for 0.8 mg/ml |
Comparison of separation results for different chiral separators utilizing CNTs, GO, and graphene.
| Separator type | CNT-doped organic polymer monolith (ref.[ | Glutamic acid-modified GO separation membrane (ref.[ | Alanine racemase chiral analogue-coated mesoporous carbon monolith (refs[ | Carbon nanoparticle-modified separation system with dextrin (ref.[ | MOD1 mesoporous 3D GNS | MOD3 Mesoporous 3D GNS |
|---|---|---|---|---|---|---|
| Reported selectivity α | 1.1 ÷ 2.89 depending on separated compound | 2 (max) | 1 ÷ 2.5 depending on separated compound | 17.5 (for thalidomide) | 12.5 (for ibuprofen) | |
| Reported resolution | 1.31 ÷ 2.87 depending on separated compound | 90–95% separation | 0.8–4.3 depending on separated compound | baseline separation for 0.05 mg/ml of thalidomide | baseline separation for 0.8 mg/ml of ibuprofen | |
| Separated chiral compound | Celiprolol, chlorpheniramine, cizolirtine and others (ref.[ | D,L-DOPA (see ref.[ | Phenylalanine, serine, tryptophan | Sulconazole, ketoconazole, citalopram hydrochloride, nefopam hydrochloride | thalidomide, ibuprofen | ibuprofen, thalidomide |
| Functional role and separation technique it is designed for | Chiral stationary phase for HPLC | Membrane material for membrane filtration | Adsorbing material, adsorption | Electrode material for capillary electro kinetic chromatography | Chiral stationary phase for HPLC | Chiral stationary phase for HPLC |
Figure 4Scheme of chemical reaction of the modification 1 (MOD1): the addition of carbonyl yilide (synthesis of TCNEO-modified 3D GNS).
Figure 5The modification step 2 (MOD2): hydrolysis of TCNEO-modified 3D GNS.
Figure 6Modification 3 (MOD3): Attachment of (s)-(+)-pyrrolidinemethanol to 3D GNS after modifications 1 and 2.